Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Rhea-AI Summary

Bluejay Diagnostics (NASDAQ: BJDX) announced an abstract acceptance for the 2026 SAEM Annual Meeting, May 18–21, 2026 in Atlanta.

The presentation reports SYMON-I pilot results linking emergency department IL-6 levels to organ dysfunction (SOFA) over the first three hospital days and notes the ongoing SYMON-II validation study.

Key Figures

SAEM 2026 dates: May 18–21, 2026 Hospitalization window: First three days

2 metrics

SAEM 2026 dates May 18–21, 2026 Society of Academic Emergency Medicine Annual Meeting in Atlanta

Hospitalization window First three days SOFA scores assessed during first three days of hospitalization

Market Reality Check

Price: $2.03 Vol: Price up 5.73% on very li...

low vol

$2.03 Last Close

Volume Price up 5.73% on very light volume: 13,745 shares vs 536,371 20-day average (about 3% of typical activity). low

Technical Shares at $2.03, trading below 200-day MA of $5.50 and down 95.02% from the $40.80 52-week high, but 19.41% above the $1.70 52-week low.

Peers on Argus

BJDX is up 5.73%, while momentum-screen peers NUWE and VTAK are both down (about...

2 Down

BJDX is up 5.73%, while momentum-screen peers NUWE and VTAK are both down (about -1.48% and -2.50%). This points to a stock-specific reaction to the SYMON-I abstract rather than a sector-wide move.

Historical Context

5 past events · Latest: Mar 06 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 06	Corporate outlook	Negative	-2.1%	2026 strategic priorities, cash position, losses and capital needs highlighted.
Feb 20	Warrant exercises	Positive	+1.5%	All prefunded warrants exercised, simplifying capital structure and share count.
Feb 17	Clinical enrollment	Positive	+0.8%	SYMON II enrollment progress and manufacturing readiness milestones reported.
Jan 27	Reverse split	Negative	-3.9%	1-for-4 reverse stock split and proportional adjustment of warrants announced.
Dec 29	Antibody production	Positive	-3.0%	Completion of commercial-scale IL-6 antibody production for Symphony cartridges.

Pattern Detected

Across the last five events, price moves generally aligned with news tone, with modest gains on operational progress and selling pressure around capital structure actions; one positive operational update saw a negative reaction.

Recent Company History

Over the past months, Bluejay has focused on advancing its Symphony IL-6 platform and strengthening its balance sheet. A Jan 27 reverse split restructured the share count, followed by Feb 17–20 updates on SYMON II enrollment and warrant exercises, leaving about 972,000 shares outstanding. A Mar 6 corporate update and 10-K highlighted cash needs and strategic priorities. Today’s SAEM abstract acceptance extends the clinical narrative by adding multicenter SYMON-I data on IL-6 and organ dysfunction in sepsis.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-23

An effective S-3 resale registration filed on Oct 23, 2025 covers up to 6,930,000 shares held by selling stockholders from the October 2025 financing. The company itself is not selling shares under this prospectus and would receive cash only if outstanding warrants registered there are exercised.

Market Pulse Summary

This announcement highlights acceptance of new SYMON-I data on emergency department IL-6 levels and ...

Analysis

This announcement highlights acceptance of new SYMON-I data on emergency department IL-6 levels and early organ dysfunction in sepsis at the 2026 SAEM meeting, adding clinical depth around Bluejay’s Symphony IL-6 test. It follows prior updates on SYMON II enrollment, manufacturing readiness, and financing activity. Investors may watch for detailed study metrics, progress on the larger SYMON II validation trial, regulatory interactions, and how existing resale registration arrangements intersect with the company’s ongoing capital needs.

Key Terms

interleukin-6, il-6, sepsis, septic shock, +2 more

6 terms

interleukin-6 medical

"a multicenter pilot clinical study evaluating interleukin-6 (IL-6) levels in patients"

Interleukin-6 is a small signaling protein the body releases to coordinate inflammation and immune responses, acting like a fire alarm that summons immune cells to sites of infection or tissue damage. It matters to investors because high or persistent levels are linked to disease activity and are a common drug target or clinical trial biomarker; changes in IL-6-related data can influence a therapy's approval prospects, market potential, and a company's valuation.

il-6 medical

"Symphony™ IL-6 Test has been accepted for presentation"

Interleukin-6 (IL-6) is a small signaling protein the body releases as an alarm during infection, injury, or chronic inflammation; think of it as a smoke detector that calls immune cells to action. It matters to investors because IL-6 levels can serve as a biomarker for disease severity and a target for therapies—drugs that block or modulate IL-6 can change treatment outcomes, regulatory decisions, and commercial prospects in healthcare markets.

sepsis medical

"organ dysfunction in sepsis patients to be presented"

Sepsis is a dangerous medical condition in which an infection triggers the body's defenses to damage its own tissues and organs, often leading to organ failure and emergency hospital care. For investors it matters because sepsis drives demand for diagnostics, antibiotics, intensive-care treatments and hospital resources, affects healthcare costs and insurer payouts, and can influence the commercial prospects and valuation of companies developing related tests, drugs and devices.

septic shock medical

"patients with sepsis and septic shock"

Septic shock is a life-threatening condition caused by a severe bodily response to infection that leads to dangerously low blood pressure and failing organs. Think of it like a city’s emergency systems collapsing after a major storm: hospitals need intensive care, special drugs and equipment, and longer stays. For investors, its incidence and treatment options matter because they affect demand for drugs, medical devices, hospital resources, trial outcomes, regulatory attention and potential liability costs.

intensive care unit (icu) medical

"patients with sepsis who were admitted or intended for admission to the intensive care unit (ICU)"

An intensive care unit (ICU) is a hospital ward equipped to monitor and treat patients with life-threatening illnesses or injuries using specialized staff and advanced machines, like heart monitors and breathing support. For investors, ICU capacity and utilization signal demand for high-cost hospital services, influence revenue and resource needs, and act like a barometer of health-system strain—similar to a company’s production line showing how busy and capital-intensive operations are.

biomarker medical

"evaluating IL-6 as a potential biomarker in the early assessment"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

AI-generated analysis. Not financial advice.

New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented.

ACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid near-patient tests for critical care conditions, today announced that an abstract related to its Symphony™ IL-6 Test has been accepted for presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting, which will take place May 18–21, 2026 in Atlanta, Georgia.

The presentation will report findings from SYMON-I, a multicenter pilot clinical study evaluating interleukin-6 (IL-6) levels in patients with sepsis who were admitted or intended for admission to the intensive care unit (ICU). The analysis evaluates the relationship between IL-6 levels measured in the emergency department and organ dysfunction as assessed by Sequential Organ Failure Assessment (SOFA) scores during the first three days of hospitalization.

Nathan Shapiro, M.D., Vice Chairman of Emergency Medicine Research at Beth Israel Deaconess Medical Center and Professor of Emergency Medicine at Harvard Medical School and the clinical trial national principal investigator, stated:

“The findings from the SYMON-I study suggest that IL-6 measured in the emergency department may be associated with subsequent organ dysfunction in patients with sepsis and septic shock. These data contribute to the growing body of evidence evaluating IL-6 as a potential biomarker in the early assessment of critically ill patients.”

Mark Feinberg, M.D., Chief Medical Advisor at Bluejay Diagnostics and Professor of Medicine at Harvard Medical School, commented:

“The SAEM Annual Meeting provides an opportunity to present emerging clinical data evaluating IL-6 as a biomarker associated with the inflammatory response and organ dysfunction in sepsis. Bluejay’s ongoing SYMON-II validation study is intended to further evaluate IL-6 as a prognostic biomarker associated with mortality and other clinically meaningful outcomes in critically ill patients.”

Presentation Details

Title: Emergency Department Interleukin-6 Levels and Organ Dysfunction in Sepsis Across Multiple Centers
Presenters: John H. Lee, M.D., Ph.D.; Nathan Shapiro, M.D.
Conference: Society of Academic Emergency Medicine (SAEM) Annual Meeting
Location: Atlanta, Georgia

About the Symphony IL-6 Test:

The Symphony™ Test platform is designed to determine patient acuity for triage and monitoring based on the measurement of a specific biomarker. The Symphony™ IL-6 Test to determine patient acuity for sepsis triage and monitoring (“Symphony™ IL-6 Test”) is currently Bluejay’s lead product candidate.

Note: Investigational device. Limited by United States law to investigational use.

About the SYMON Clinical Study Program:

The SYMON Clinical Study Program includes SYMON-I (clinicaltrials.gov ID NCT06181604), SYMON-II (NCT06654895), and SYMON-III (NCT07425587). SYMON-I is a pilot study to determine IL-6 levels associated with various endpoints, including, but not limited to 28-day all-cause mortality and in-hospital mortality. The SYMON-II study is the pivotal study to validate the outcomes of the SYMON-I study, which the Company plans to use to support a 510(k) application to the FDA. The SYMON-III study is a pilot study to determine IL-6 levels associated with patients presenting with increasing severity of infection in the emergency department and risk of developing sepsis.

About Bluejay Diagnostics:

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.

Forward-Looking Statements:

This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.

Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
neil.dey@bluejaydx.com
978-631-0310

Website: www.bluejaydx.com

FAQ

What did Bluejay (BJDX) announce for the SAEM 2026 meeting on May 18–21?

Bluejay will present SYMON-I clinical data on IL-6 and organ dysfunction in sepsis at SAEM 2026. According to Bluejay, the abstract reports a multicenter pilot analysis relating ED IL-6 levels to SOFA-assessed organ dysfunction during the first three hospital days.

What does the SYMON-I study presented by BJDX evaluate?

SYMON-I evaluates interleukin-6 measured in the emergency department and its association with organ dysfunction. According to Bluejay, the multicenter pilot used SOFA scores during the first three days to assess the relationship in patients admitted or intended for ICU care.

Who will present Bluejay's SYMON-I findings at SAEM 2026?

Presenters listed are John H. Lee, M.D., Ph.D., and Nathan Shapiro, M.D. According to Bluejay, Nathan Shapiro is the national principal investigator and the study includes collaborators across multiple centers reporting IL-6 and SOFA score analyses.

How does Bluejay describe the clinical relevance of the SYMON-I results for BJDX investors?

The company says SYMON-I suggests ED IL-6 may associate with later organ dysfunction in sepsis patients. According to Bluejay, these pilot data support further validation in SYMON-II to evaluate prognostic links to mortality and other clinical outcomes.

When and where will Bluejay present the SYMON-I abstract for BJDX investors to note?

The abstract will be presented at the Society of Academic Emergency Medicine Annual Meeting, May 18–21, 2026, in Atlanta, Georgia. According to Bluejay, the presentation will report multicenter emergency department IL-6 and organ dysfunction findings from SYMON-I.